Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
08/2003
08/28/2003US20030162778 Carbocyclic side chain containing metalloprotease inhibitors
08/28/2003US20030162777 Administering a biheterocyclic compounds containing aminocarbonyl, aminothiocarbonyl or aminosulfonyl group for treating neuromuscular dysfunction of the lower urinary tract in a mammal in need of such treatment
08/28/2003US20030162776 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
08/28/2003US20030162775 Heterocyclic substituted pyrazolones
08/28/2003US20030162774 Derivatives of sulfonylurea, sulfonylthiourea, sulfonylguanidine, thioacylsufonamide and acylsulfonamide; useful for treating thromobis
08/28/2003US20030162772 For example, N-(2-(3-((1-(3,4-dichlorobenzylpiperidinyl) aminohydroxypropoxy)phenyl)acetamide; use as modulators of chemokine receptor activity, and may be used in treatment of autoimmune, inflammatory, proliferative diseases
08/28/2003US20030162771 Have an antagonistic activity with respect to corticotropin releasing factor
08/28/2003US20030162770 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
08/28/2003US20030162765 Use in treatment and prevention of central nervous system and other disorders
08/28/2003US20030162764 Pyrimidine A2b selective antagonist compounds, their synthesis and use
08/28/2003US20030162756 For delaying or preventing conversion of mild cognitive impairment into dementia, especially Alzheimer's Disease
08/28/2003US20030162749 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
08/28/2003US20030162748 Comprises liposomes attached to prodrugs through phosphonate linkages; phospholipases; targets liver/spleen
08/28/2003US20030162743 Matrix metalloproteinase and tumor necrosis factor inhibitors
08/28/2003US20030162739 Antisense molecules and method of controlling expression of gene function by using the same
08/28/2003US20030162736 Medicament comprising NK4 gene or recombinant NK4 protein
08/28/2003US20030162727 Use of cyp1b1inhibitors for treating cancer
08/28/2003US20030162722 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase I and II inhibitors
08/28/2003US20030162719 Immobilization of active materials
08/28/2003US20030162717 Suppression appetite; weight loss therapy
08/28/2003US20030162291 Clk-2, cex-7 and coq-4 genes, and uses thereof
08/28/2003US20030162274 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/28/2003US20030162196 Isolation nucleic acids; genetic engineering; diagnosis, therapy, prevention hematopoietic, nervous system disorders
08/28/2003US20030162175 NK cell receptor polynucleotides, polypeptides, and antibodies
08/28/2003US20030161903 Comprises solvent extract of compressed cake derived from defatted evening primrose seed wherein effective component contains polyphenol-essential elements such as ellagic acid, gallic acid, pentagalloylglucose and catechin
08/28/2003US20030161883 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
08/28/2003US20030161867 Skin-permeable selective cyclooxygenase-2 inhibitor composition
08/28/2003US20030161834 Adjuvant compositions comprising a saponin and and an immunostimulatory oligonucleotide containing unmethylated CpG (a cytosine guanosine dinucleotide DNA motif); synergistic induction of antigen; anticarcinogenic agents
08/28/2003US20030161826 Therapy for autoimmune disease; central nervous system disorders
08/28/2003US20030161809 Complexes; drug delivery
08/28/2003US20030161788 System for monitoring bacterial tumor treatment
08/28/2003CA2512020A1 Compositions and methods for delivery of skin cosmeceuticals
08/28/2003CA2486381A1 Lipase inhibiting composition
08/28/2003CA2477117A1 Pyrrolopyrimidine derivative
08/28/2003CA2477116A1 Pyrrolopyrimidine derivatives
08/28/2003CA2477014A1 Rna interference mediated inhibition of tnf and tnf receptor superfamily gene expression using short interfering nucleic acid (sina)
08/28/2003CA2476822A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
08/28/2003CA2476771A1 A preparation and method for weight reduction
08/28/2003CA2476679A1 Vitamin d3 derivatives and remedies using the same
08/28/2003CA2476624A1 Azabicyclic compounds for the treatment of disease
08/28/2003CA2476451A1 Hyaluronic acid mediated adenoviral transduction
08/28/2003CA2476437A1 Chemosensitizing with liposomes containing oligonucleotides
08/28/2003CA2476434A1 Method of treating trx mediated diseases
08/28/2003CA2476427A1 Partial peptide mimetics and methods
08/28/2003CA2476422A1 Topiramate salts and compositions comprising and methods of making and using the same
08/28/2003CA2476417A1 Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
08/28/2003CA2476411A1 Thiazolyl urea compounds for the treatment of cancer
08/28/2003CA2476406A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
08/28/2003CA2476376A1 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
08/28/2003CA2476115A1 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
08/28/2003CA2476112A1 Rna interference mediated inhibition of interleukin gene expression using short interfering nucleic acid (sina)
08/28/2003CA2475923A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
08/28/2003CA2475879A1 Synthesis of quinazolinones
08/28/2003CA2475600A1 Method for producing high-quality hydrophobic licorice extract
08/28/2003CA2475374A1 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
08/28/2003CA2475123A1 Desolvating solvates of atorvastatin hemi-calcium
08/28/2003CA2474848A1 Novel tyloindicines and related processes, pharmaceutical compositions and methods
08/28/2003CA2474785A1 Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative
08/28/2003CA2474671A1 Methods for determining the influence of protein binding on antiretroviral activity
08/28/2003CA2473100A1 Pyranones useful as atm inhibitors
08/28/2003CA2471421A1 Rna interference mediated inhibition of protein typrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina)
08/28/2003CA2460055A1 Insulin and igf-1 receptor agonists and antagonists
08/28/2003CA2459532A1 Rna interference by modified short interfering nucleic acid
08/28/2003CA2419685A1 Antidiabetic agents
08/27/2003EP1338655A1 Substance inhibiting the binding of signal transducing molecule to kdr/flk-1 phosphorylated at tyrosine at the 1175-position and method of using the same
08/27/2003EP1338651A1 Method of screening remedy for diabetes
08/27/2003EP1338605A1 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres
08/27/2003EP1338597A1 1,4,5,6-tetrahydroimidazo 4,5-d]diazepine derivatives or salts thereof
08/27/2003EP1338303A1 Detoxifying phytotherapeutic composition from two plant extracts and process for preparing the same
08/27/2003EP1338282A1 Uridine derivatives as Matrix Metalloproteinase (MMP) and Tumor Necrosis Factor (TNF) inhibitors for the treatment of cancer
08/27/2003EP1338269A1 Composition for whitening the skin and alleviating of pigmentation disorders containing creatinine and/or a creatinine derivative as active ingredient
08/27/2003EP1337859A1 Selective anxiolytic therapeutic agents
08/27/2003EP1337854A2 Method for screening anti-proliferative compounds and inhibiting tumor growth
08/27/2003EP1337661A1 Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism
08/27/2003EP1337639A2 Master bone formation transcription factor: compositions and methods of use
08/27/2003EP1337634A2 Novel polypeptides involved in immune response
08/27/2003EP1337633A2 Anti-angiogenic proteins and fragments and methods of use thereof
08/27/2003EP1337632A2 Differentiated cells suitable for human therapy
08/27/2003EP1337560A2 Truncated cd200
08/27/2003EP1337550A2 Hepatitis c tripeptide inhibitors
08/27/2003EP1337544A2 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme
08/27/2003EP1337540A2 Motilide compounds
08/27/2003EP1337535A2 Benzodiazepine derivatives as gaba a receptor modulators
08/27/2003EP1337528A2 Benzothiophene derivative compounds, process of preparation and use thereof
08/27/2003EP1337527A1 Indolylmaleimide derivatives as protein kinase c inhibitors
08/27/2003EP1337526A1 Substituted imidazoles useful in the treatment of inflammatory diseases
08/27/2003EP1337524A1 Substituted quinolines as antitumor agents
08/27/2003EP1337523A2 2,4-substituted pyridine derivatives
08/27/2003EP1337522A1 0ovel farnesyl protein transferase inhibitors
08/27/2003EP1337518A1 Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
08/27/2003EP1337517A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis
08/27/2003EP1337513A1 4-substituted quinolines as antitumor agents
08/27/2003EP1337512A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
08/27/2003EP1337511A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity
08/27/2003EP1337283A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency
08/27/2003EP1337275A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
08/27/2003EP1337273A2 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
08/27/2003EP1337272A2 Combination of gaba agonists and aldose reductase inhibitors
08/27/2003EP1337269A2 Association of calpain inhibitors and reactive oxygen species trapping agents
08/27/2003EP1337267A1 Use of blood coagulation factor xiii for treating haemophilia a
1 ... 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 ... 1564